Role of dasatinib in the management of lung cancer: A meta-analysis of clinical trials

Abdalla,Berun A.; Ali,Rebaz M.; Kakamad,Fahmi H.; Ahmed,Harem K.; Ali,Rawa M.; Abdullah,Ari M.; Yasseen,Hadeel A.; Fattah,Fattah H.; Hama Rashid,Diyar Jaafar; Karim,Sanaa O.; Mahmood,Yousif M.; Hasan,Sabah J.; Hamasaeed,Ahmed G.

doi:10.3892/br.2025.1929

Role of dasatinib in the management of lung cancer: A meta-analysis of clinical trials

Authors:
- Berun A. Abdalla
- Rebaz M. Ali
- Fahmi H. Kakamad
- Harem K. Ahmed
- Rawa M. Ali
- Ari M. Abdullah
- Hadeel A. Yasseen
- Fattah H. Fattah
- Diyar Jaafar Hama Rashid
- Sanaa O. Karim
- Yousif M. Mahmood
- Sabah J. Hasan
- Ahmed G. Hamasaeed
View Affiliations

Affiliations: Scientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq, College of Medicine, University of Sulaimani, Sulaymaniyah, Kurdistan 46001, Iraq
Published online on: January 23, 2025 https://doi.org/10.3892/br.2025.1929
Article Number: 51
Copyright: © Abdalla et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer, particularly non‑small cell lung cancer (NSCLC), the leading cause of cancer‑related deaths worldwide, has prompted extensive research into innovative treatments, including targeted therapies. The present meta‑analysis aims to evaluate the efficacy of dasatinib, both as monotherapy and in combination with other therapies, for the treatment of lung cancer. Adhering to the PRISMA guidelines, a meticulous, thorough review of clinical trials was conducted across reputable databases, including Google Scholar, PubMed/MEDLINE, and EMBASE, focusing on studies published in English up to May 5th, 2024. Inclusion criteria were restricted to randomized clinical trials (RCTs) assessing the efficacy of dasatinib, either as a standalone therapy or in combination with other treatments. The search identified 55 studies, of which nine RCTs met the inclusion criteria: four phase II, three phase I, and two phase I/II. A total of 234 patients participated, with 107 receiving dasatinib alone and 127 undergoing combination therapy. Histological analyses revealed that 79.1% of patients had non‑small cell lung cancer, with adenocarcinoma being the predominant subtype (63.8%), followed by squamous cell carcinoma (22.1%). Treatment responses varied, with 52.4% of the patients in the dasatinib alone group experiencing progressive disease, while 38.3% achieved stable disease; by contrast, 29.6% of patients in the combination therapy showed progressive disease. Adverse events, including anemia and fatigue, were more prevalent with combination therapies. Dasatinib treatment shows potential for improving overall survival with fewer adverse events compared with combination therapies in patients with lung cancer; however, large‑scale clinical trials are essential to confirm its efficacy as a standalone treatment.

View Figures

View References

1	Siddiqui F, Vaqar S and Siddiqui AH: Lung Cancer. StatPearls Publishing, Treasure Island, FL, 2024.
2	Thandra KC and Barsouk A, Saginala K, Aluru JS and Barsouk A: Epidemiology of lung cancer. Contemp Oncol (Pozn). 25:45–52. 2021.PubMed/NCBI View Article : Google Scholar
3	Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164. 2020.PubMed/NCBI View Article : Google Scholar
4	Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc. 83:355–367. 2008.
5	Mingomataj E, Krasniqi M, Dedushi K, Sergeevich KA, Kust D, Qadir AA, Abdullah AS, Ahmed MK and Fatah GM: Cancer publications in one year (2023): A cross-sectional study. Barw Med J. 2:3–11. 2024.
6	Ali RM, Omar SS, Ahmed HK, Omar DA, Mahmood YM, Mustafa MQ, Abdullah AS, Hassan MN, Hussein DA, Kakamad SH, et al: Effect of sunitinib in the management of lung cancer: A systematic review of clinical trials. Barw Med J. 2:57–64. 2024.
7	Alduais Y, Zhang H, Fan F, Chen J and Chen B: Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine (Baltimore). 102(e32899)2023.PubMed/NCBI View Article : Google Scholar
8	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008.PubMed/NCBI View Article : Google Scholar
9	Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, Myers RW and Lutrin CL: Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 60:1573–1581; discussion 1581-1582. 1995.PubMed/NCBI View Article : Google Scholar
10	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016.PubMed/NCBI View Article : Google Scholar
11	Ye Q, Gui C, Jin D, Zhang J, Zhang J, Ma N and Xu L: Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway. Biomed Pharmacother. 173(116445)2024.PubMed/NCBI View Article : Google Scholar
12	Abdullah HO, Abdalla BA, Kakamad FH, Ahmed JO, Baba HO, Hassan MN, Bapir R, Rahim HM, Omar DA, Kakamad SH, et al: Predatory publishing lists: A review on the ongoing battle against fraudulent actions. Barw Med J. 2:26–30. 2024.
13	Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, et al: Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 28:4609–4615. 2010.PubMed/NCBI View Article : Google Scholar
14	Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, et al: Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 28:1387–1394. 2010.PubMed/NCBI View Article : Google Scholar
15	Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, et al: A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 19:1040–1041. 2014.PubMed/NCBI View Article : Google Scholar
16	Kelley MJ, Jha G, Shoemaker D, Herndon JE II, Gu L, Barry WT, Crawford J and Ready N: Phase II study of dasatinib in previously treated patients with advanced non-small cell lung cancer. Cancer Invest. 35:32–35. 2017.PubMed/NCBI View Article : Google Scholar
17	Kim C, Liu SV, Crawford J, Torres T, Chen V, Thompson J, Tan M, Esposito G, Subramaniam DS and Giaccone G: A phase I trial of dasatinib and osimertinib in TKI naïve patients with advanced EGFR-mutant non-small-cell lung cancer. Front Oncol. 11(728155)2021.PubMed/NCBI View Article : Google Scholar
18	Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ and Haura EB: Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor-(EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Br J Cancer. 120:791–796. 2019.PubMed/NCBI View Article : Google Scholar
19	Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA and Vokes EE: Cancer and Leukemia Group B (CALGB). A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (cancer and leukemia group B 30602). J Thorac Oncol. 5:380–384. 2010.PubMed/NCBI View Article : Google Scholar
20	Khurshid H, Dipetrillo T, Ng T, Mantripragada K, Birnbaum A, Berz D, Radie-Keane K, Perez K, Constantinou M, Luppe D, et al: A phase I study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer. Front Oncol. 2(56)2012.PubMed/NCBI View Article : Google Scholar
21	Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE and Hammerman PS: Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 8:1434–1437. 2013.PubMed/NCBI View Article : Google Scholar
22	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI View Article : Google Scholar
23	Luo W: Nasopharyngeal carcinoma ecology theory: Cancer as multidimensional spatiotemporal ‘unity of ecology and evolution’ pathological ecosystem. Theranostics. 13:1607–1631. 2023.PubMed/NCBI View Article : Google Scholar
24	World Health Organization: Lung cancer. https://www.who.int/news-room/fact-sheets/detail/lung-cancer. Accessed November 4, 2024.
25	Chen BT, Chen Z, Ye N, Mambetsariev I, Fricke J, Daniel E, Wang G, Wong CW, Rockne RC, Colen RR, et al: Differentiating peripherally-located small cell lung cancer from non-small cell lung cancer using a CT radiomic approach. Front Oncol. 10(593)2020.PubMed/NCBI View Article : Google Scholar
26	Ruano-Ravina A, Provencio M, Calvo de Juan V, Carcereny E, Estival A, Rodríguez-Abreu D, Benítez G, López-Castro R, Belver M, Guirado-Risueño M, et al: Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study. Transl Lung Cancer Res. 10:3902–3911. 2021.PubMed/NCBI View Article : Google Scholar
27	Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, Rangachari D and Costa DB: Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open. 4(e2037120)2021.PubMed/NCBI View Article : Google Scholar
28	Bitenc M, Cufer T, Kern I, Miklavcic M, Petrovic S, Groznik V and Sadikov A: Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer. Radiol Oncol. 56:346–354. 2022.PubMed/NCBI View Article : Google Scholar
29	Lee SH: Chemotherapy for lung cancer in the era of personalized medicine. Tuberc Respir Dis (Seoul). 82:179–189. 2019.PubMed/NCBI View Article : Google Scholar
30	Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, Bonomo L, Del Grande F, Casiraghi M, De Marinis F and Spaggiari L: Stage III non-small-cell lung cancer: An overview of treatment options. Curr Oncol. 30:3160–3175. 2023.PubMed/NCBI View Article : Google Scholar
31	Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z and Zhang W: Current treatments for non-small cell lung cancer. Front Oncol. 12(945102)2022.PubMed/NCBI View Article : Google Scholar
32	Omar SS, Ali RH, Abdullah SH, Hussein DM, Radha BMM, Latif AB, Ali SM, Hiwa DS, Ahmed HK, Hamasaeed AG, et al: Durvalumab (Anti-PD-1) in the management of mesothelioma: A systematic review of the current literature. Barw Med J. 1:32–39. 2023.
33	Ali RM, Kakamad FH, Abdullah HO, Abdulla SH, Ahmed SF, Amin BJH, Hassan MN, Hasan SJ, Hamasalih HM, Abdalla BA, et al: Pembrolizumab (Anti-PD-1) immunotherapy in malignant pleural mesothelioma: A systematic review of the current literature. Barw Med J. 1:6–13. 2023.
34	Park NS, Park YK, Yadav AK, Shin YM, Bishop-Bailey D, Choi JS, Park JW and Jang BC: Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms. J Cell Mol Med. 25:8300–8311. 2021.PubMed/NCBI View Article : Google Scholar
35	Conchon M, Freitas CM, Rego MA and Braga Junior JW: Dasatinib-clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev Bras Hematol Hemoter. 33:131–139. 2011.PubMed/NCBI View Article : Google Scholar
36	Shyam Sunder S, Sharma UC and Pokharel S: Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 8(262)2023.PubMed/NCBI View Article : Google Scholar